Zhejiang Orient Gene Biotech Co Ltd (688298) — Capital Reinvestment Ratio
Zhejiang Orient Gene Biotech Co Ltd (688298) has a Capital Reinvestment Ratio of 0.39x as of September 2022, meaning it reinvests 0% of its operating cash flow (CN¥309.89 Million) in capital expenditures (CN¥119.58 Million). See 688298 net asset quality score to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Zhejiang Orient Gene Biotech Co Ltd Capital Reinvestment Ratio (2016–2022)
This chart tracks Zhejiang Orient Gene Biotech Co Ltd's Capital Reinvestment Ratio across 7 annual periods. Check 688298 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Zhejiang Orient Gene Biotech Co Ltd (2016–2022)
Year-by-year Capital Reinvestment Ratio for Zhejiang Orient Gene Biotech Co Ltd from 2016 to 2022. For live market cap and broader valuation context, see market value of Zhejiang Orient Gene Biotech Co Ltd.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.35x | CN¥3.00 Billion | CN¥1.05 Billion | ▲ +259.8% |
| 2021 | 0.10x | CN¥5.20 Billion | CN¥507.87 Million | ▲ +37.7% |
| 2020 | 0.07x | CN¥1.79 Billion | CN¥126.93 Million | ▼ -67.7% |
| 2019 | 0.22x | CN¥54.21 Million | CN¥11.90 Million | ▼ -48.5% |
| 2018 | 0.43x | CN¥44.33 Million | CN¥18.88 Million | ▲ +6.7% |
| 2017 | 0.40x | CN¥33.54 Million | CN¥13.38 Million | ▲ +1.3% |
| 2016 | 0.39x | CN¥11.81 Million | CN¥4.65 Million | — |